Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(33.3%)
N/A
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 1(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02597647Phase 1Completed

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

Role: collaborator

NCT03668015Not ApplicableCompleted

Xylitol and Sorbitol Effects on the Oral Microbiome

Role: collaborator

NCT03083158Phase 4Completed

Immunity to Hepatitis B Vaccine

Role: collaborator

NCT02289326Completed

Biomarker Monitoring in TP53 Mutation Carriers

Role: collaborator

NCT01834391Completed

Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients

Role: collaborator

All 5 trials loaded